Many pharma cos see positive growth

Majority number of listed pharmaceutical companies witnessed positive growth in first half of this calendar year compared to same period of the previous year as their sales increased.
Out of 27 companies listed under the category of Pharmaceuticals and Chemicals, 16 belong to pharmaceutical. Out of these 16, seven companies' whose year-end is December have disclosed their half yearly statements (unaudited).
Among the companies, the consolidated profits of Orion Pharma and Glaxo Smithkline declined during January-June, 2015 compared to the values observed during the corresponding period of the previous year.
And profits of other six companies rose during January-June, 2015 against the same period of the previous year.
The companies whose profits rose are Ambee Pharma, Beximco Pharma, Renata, ACI and Ibn Sina.  
According to information of Dhaka Stock Exchange (DSE) and IDLC Investments, Pharma sector's index rose 14.3 per cent during January-June this year. During this period, the net profit after tax of 16 companies, including another nine chemical companies, was Tk 3.97 billion.
Ambee Pharma showed its profit after tax for January-June, 2015 above 4.12 million against Tk 3.81 million for same period of the previous year. The company's Net Operating Cash Flow Per Share (NOCFPS) was Tk. 1.30 for Jan-June, 2015 as against Tk. 1.10 for Jan-June, 2014, whereas the net asset value (NAV) per share was Tk. 25.93 as of June 30, 2015 and Tk. 24.21 as of December 31, 2014.
Beximco Pharma showed its profit after tax for Jan-June, 2015 above Tk. 1.0 billion with EPS of Tk. 2.61 as against Tk. 724.27 million and Tk. 1.88 respectively for same period of the previous year.
Asked, a senior official of the Beximco Pharma said their company's sales rose 17.48 per cent or Tk 930 million to close at Tk 6.25 billion during January to June of this year.  
Orion Pharma showed its consolidated profit after tax for January-June, 2015 Tk 503.10 million with EPS of Tk 2.15 as against Tk 709.02 million and Tk 3.03 respectively for same period of the previous year.
Renata reported its profit after tax for January-June, 2015 above Tk 1.03 billion with EPS of Tk 19.46 as against Tk 816.01 million and Tk 15.41 respectively for same period of the previous year. The company's NOCFPS also rose during January-June than the value observed during same period of the previous year.  The company's consolidated NOCFPS stood at Tk 163.65 as of June 30, 2015 and Tk 150.86 as of December 31, 2014.
Consolidated profit after tax of ACI for January-June, 2015 stood at above Tk. 2.39 billion with consolidated basic EPS of Tk. 60.28 as against Tk. 158.31 million and Tk. 4.01 respectively for the same period of the previous year.
Profit of ACI sharply rose 1403 per cent mainly because of extra ordinary income came from brand selling. Otherwise, the company's growth also remained consistent.
"Of total profit incurred during January-June, 2015 Tk 2.52 billion came from brand sale of ACI,' an official of ACI said.
Ibn Sina showed its profit after for January-June, 2015 Tk 54.11 million with EPS of Tk 2.41 as against Tk 37.72 million and Tk 1.68 for same period of the previous year. The company's NOCFPS was Tk. 2.24 for January-June, 2015 as against Tk. 3.85 for Jan-June, 2014, whereas the NAV per share was Tk. 26.89 as of June 30, 2015 and Tk. 29.40 as of June 30, 2014.
Profit after and tax of Glaxo Smithkline for January-June, 2015 were Tk was Tk. 371.43 million with EPS of Tk. 30.83 as against Tk. 410.53 million and Tk. 34.08 respectively for the same period of the previous year.
Md. Nizamuddin, deputy company secretary of Glaxo Smithkline, said their company's sales and profits declined as they cannot promote products through 'unethical' practice.
"Our management is capable to run business. But they discourage the gifts for doctors. That's why only brochure is provided to doctors," said Nizamuddin.
He, however, expressed optimism that their profits would increase based on company's effort.
[email protected]